Thyrocare owner Velumani success story: The Man Who Started from Rs 150/month? Now Owns Rs 1,320 Crores Company.
Thyrocare Velumani Success Story:
This is a Real story of a person who lives in a small home and poor family background, but he Built Rs 1,320 crores worth company with the invest of his hard work, dedication, and consistency that is Thyrocare Velumani. This real story is about a man who was born to a poor farmer lives in an obscure village of Appanickenpatti Padur in Tamil Nadu state.
A person who had no resources, who had to seek government subsidy in order to complete his school and college education.
Thyrocare: A Thyroid testing company:
Thyrocare Velumani: today he owns, one of the largest thyroid testing company, that having around 1,122 outlets across India, Bangladesh, Middle East and Nepal. Still, he spends most of his nights at lab through his living quarters are about the lab in Mumbai.
Thyrocare Velumani started his career in Gemini Capsules as a chemist in 1979, his starting salary was 150/- per month. Gemini capsules is a small pharmaceutical company in Coimbatore. But just after there the company was shut down and he had to lose his job too.
After sometimes he got another job at Bhabha Atomic Research Centre (BARC) for the post of laboratory assistant which lasted for about 14 years. In between these years, he was promoted to the rank of the scientist as he had completed his Doctor’s degree.
At the age of 37, Thyrocare Velumani took the decision to start his own thyroid testing laboratory in 1996 with Rs. 1,00,000 from his provident fund. It was that time when he worked on the business model and offered to test at very affordable rates.
As Per May 2016 Stats, Thyrocare is worth 3,377 crores and has made its debut on Indian bourses! 64% of the stake rest with Velumani which makes him worth Rs 2,158 crore!
Thyrocare has been working on developing a subsidiary to focus on cancer screening through molecular imaging.
Thanks for reading, follow us on Facebook for more updates. Let us know your opinions in the comments section.